An anoikis-related gene signature predicts prognosis and immunotherapy response, and identifies CCAR2 as a therapeutic target in triple-negative breast cancer.

The high-risk group showed a trend toward a higher predicted non-response rate based on the TIDE algorithm, suggesting a potentially poorer response to immunotherapy that warrants further investigation ( Figure 2I ).

also in 53,322 other papers